International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics

International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics

This article continues the comprehensive internationalconsensus (ICON) statement on allergen immunotherapy(AIT). The initial article also recently appeared in theJournal. The conclusions below focus on key mechanisms ofAIT-triggered tolerance, requirements in allergenstandardization, AIT cost-effectiveness, and regulatoryguidance. Potential barriers to and facilitators of the use ofAIT are described in addition to future directions.International allergy specialists representing the EuropeanAcademy of Allergy and Clinical Immunology; the AmericanAcademy of Allergy, Asthma & Immunology; the AmericanCollege of Allergy, Asthma and Immunology; and the WorldAllergy Organization critically reviewed the existingliterature and prepared this summary of recommendationsfor best AIT practice. The authors contributed equally andreached consensus on the statements presented herein. (JAllergy Clin Immunol 2016;137:358-68.)